IKK-β also known as inhibitor of nuclear factor kappa-B kinase subunit beta is a
protein that in humans is encoded by the IKBKB (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta)
gene.
IKK-β plays a significant role in
braincells following a
stroke.[5] If
NF-κB activation by IKK-β is blocked, damaged cells within the brain stay alive, and according to a study performed by the
University of Heidelberg and the University of Ulm, the cells even appear to make some recovery.[6]
Inhibition of IKK and IKK-related kinases has been investigated as a therapeutic option for the treatment of inflammatory diseases and cancer.[7] The small-molecule inhibitor of IKK2 SAR113945, developed by Sanofi-Aventis, was evaluated in patients with knee osteoarthritis.[8]
^May MJ, D'Acquisto F, Madge LA, Glöckner J, Pober JS, Ghosh S (September 2000). "Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex". Science. 289 (5484): 1550–4.
Bibcode:
2000Sci...289.1550M.
doi:
10.1126/science.289.5484.1550.
PMID10968790.
^Shifera AS, Horwitz MS (March 2008). "Mutations in the zinc finger domain of IKK gamma block the activation of NF-kappa B and the induction of IL-2 in stimulated T lymphocytes". Molecular Immunology. 45 (6): 1633–45.
doi:
10.1016/j.molimm.2007.09.036.
PMID18207244.
IKK-β also known as inhibitor of nuclear factor kappa-B kinase subunit beta is a
protein that in humans is encoded by the IKBKB (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta)
gene.
IKK-β plays a significant role in
braincells following a
stroke.[5] If
NF-κB activation by IKK-β is blocked, damaged cells within the brain stay alive, and according to a study performed by the
University of Heidelberg and the University of Ulm, the cells even appear to make some recovery.[6]
Inhibition of IKK and IKK-related kinases has been investigated as a therapeutic option for the treatment of inflammatory diseases and cancer.[7] The small-molecule inhibitor of IKK2 SAR113945, developed by Sanofi-Aventis, was evaluated in patients with knee osteoarthritis.[8]
^May MJ, D'Acquisto F, Madge LA, Glöckner J, Pober JS, Ghosh S (September 2000). "Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex". Science. 289 (5484): 1550–4.
Bibcode:
2000Sci...289.1550M.
doi:
10.1126/science.289.5484.1550.
PMID10968790.
^Shifera AS, Horwitz MS (March 2008). "Mutations in the zinc finger domain of IKK gamma block the activation of NF-kappa B and the induction of IL-2 in stimulated T lymphocytes". Molecular Immunology. 45 (6): 1633–45.
doi:
10.1016/j.molimm.2007.09.036.
PMID18207244.